drugset
drugset / Trial / NCT00727064

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

NCT00727064 ↗

Phase 1 Completed 14 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.

Timeline

Start
2008-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desvenlafaxine Other / unclassified — —
Comparator Venlafaxine Small molecule — —

Indications

No indication recorded.